Sierra Oncology, Inc. (SRRA) News

Sierra Oncology, Inc. (SRRA)

Today's Latest Price: $13.72 USD

0.13 (0.96%)

Updated Dec 2 3:58pm

Add SRRA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

Filter SRRA News Items

SRRA News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest SRRA News From Around the Web

Below are the latest news stories about Sierra Oncology Inc that investors may wish to consider to help them evaluate SRRA as an investment opportunity.

Sierra Oncology, Inc. (SRRA): Hedge Funds In Wait-and-See Mode

In this article you are going to find out whether hedge funds think Sierra Oncology, Inc. (NASDAQ:SRRA) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks […]

Yahoo | June 26, 2020

Sierra Oncology, Inc (SRRA) Upgraded to Buy: What Does It Mean for the Stock?

Sierra Oncology, Inc (SRRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

Yahoo | June 18, 2020

Codexis Announces the Election of New Directors at its Annual Meeting of Stockholders

Codexis, Inc. (CDXS), a leading protein engineering company and developer of high-performance enzymes, announces the election of new independent directors, Alison Moore, Ph.D. and Stephen Dilly, MBBS, Ph.D. at the company’s 2020 Annual Meeting of Stockholders held earlier today. “We are delighted to welcome these two highly qualified professionals to our board, both of whom bring exceptional experience in biotherapeutics development and commercialization at a time when we are increasing our focus on this business segment,” said Bernard J. Kelley, Codexis Chairman. Dr. Moore brings to Codexis significant experience as a biotechnology and pharmaceutical executive, including an extensive background in biomanufacturing.

Yahoo | June 16, 2020

Sierra Oncology's momelotinib shows long-term benefit in myelofibrosis

Sierra Oncology ([[SRRA]] +7.2%) announces long-term safety and dose intensity data on momelotinib, a JAK1, JAK2 and ACVR1 inhibitor, in more than 550 myelofibrosis patients. The results were presented at EHA.Over periods as long as 10 years, increases in hemoglobin levels were sustained compared to decreases in those receiving Incyte's...

Seeking Alpha | June 12, 2020

Sierra Oncology Reports Favorable Long-Term Safety and Dose Intensity Data for Momelotinib

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, announced that Long-Term Safety and Dose Intensity data for momelotinib are being presented today in two posters at the 25th European Hematology Association (EHA) Virtual Congress.

Yahoo | June 12, 2020

Sierra Oncology Appoints Dr. Stephen Dilly as President and Chief Executive Officer

Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced the appointment of Dr. Stephen Dilly as President and Chief Executive Officer, effective June 1, 2020. In addition, Dr. Dilly and Mr. Craig Collard have been appointed to the company's Board of Directors.

Yahoo | May 26, 2020

Sierra Oncology to Report Favorable Dose Intensity Data and Long-Term Safety Data for Momelotinib at the 25th European Hematology Association (EHA) Congress

Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that Dose Intensity and Long-Term Safety data for momelotinib will be presented in two posters at the 25th European Hematology Association (EHA) Virtual Congress taking place from June 11-21, 2020.

Yahoo | May 14, 2020

Sierra Oncology to Hold KOL Call to Discuss Anemia & Transfusion Dependency as Critical Unmet Needs in Myelofibrosis

Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that it will host an Analyst & Investor Call to discuss anemia and transfusion dependency, two critical unmet medical needs in treating patients with myelofibrosis, on Wednesday, May 13th at 10:00 am ET. The event will feature a presentation by renowned myelofibrosis expert Dr. Ruben Mesa, Director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center.

Yahoo | May 7, 2020

Sierra Oncology Reports First Quarter 2020 Results

Sierra Oncology Reports First Quarter 2020 Results

Yahoo | May 7, 2020

Here's Why We're Not Too Worried About Sierra Oncology's (NASDAQ:SRRA) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Yahoo | May 4, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7057 seconds.